The drug helped many patients effectively control their symptoms and maintain their improvements in personal and social functioning.
These studies provided longer-term follow-up to the three previously completed six week trials that demonstrated efficacy and tolerability for Invega in the treatment of patients with schizophrenia.
Efficacy analyses included change from baseline to end point in Positive and Negative Syndrome Scale (PANSS) total score and the Personal and Social Performance (PSP) scale, a measure of personal and social functioning.
Improvements in PANSS total score in all treatment groups were observed over the first 12 weeks of the study and were maintained throughout the remainder of the 52 week trial.